(6/6) ASCO 2017: Round up of expert discussion on the latest in prostate cancer

(5/6) ASCO 2017: ASCO highlights in prostate cancer

(4/6) ASCO 2017: Expert discussion on the latest in prostate cancer

(3/6) ASCO 2017: STAMPEDE data

(2/6) ASCO 2017: LATITUDE data

(1/6) ASCO 2017: Introduction to Expert discussion on the latest in prostate cancer

New ALK inhibitor alectinib halts lung cancer growth more than a year longer than crizotinib, with fewer severe side effects

Immunotherapy for mesothelioma could be on the horizon

Global study sets new risk-based standard to personalise chemotherapy for colon cancer after surgery

Olaparib slows growth of BRCA-related metastatic breast cancer

Low testosterone after testicular cancer could be linked to chronic health problems

Single radiation treatment can sufficiently relieve spinal cord compression symptoms